This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Novo Nordisk A/s. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000
Title: Albert Michael Crider: Innovator in Somatostatin Research
Introduction
Albert Michael Crider is a notable inventor based in Monroe, LA (US). He has made significant contributions to the field of medical research, particularly in the development of somatostatin agonists and antagonists. With a total of 2 patents, Crider's work is recognized for its potential impact on treating various medical disorders.
Latest Patents
Crider's latest patents include innovative compounds designed to interact with human somatostatin receptor subtypes. The first patent, titled "Constrained somatostatin agonists and antagonists," focuses on a compound of general formula I, which aims to treat medical disorders related to binding to these receptors. This invention highlights the importance of targeted therapies in modern medicine.
Career Highlights
Crider is currently associated with Novo Nordisk A/S, a leading global healthcare company. His role at Novo Nordisk allows him to collaborate with other experts in the field and contribute to groundbreaking research in diabetes care and hormone-related therapies.
Collaborations
Some of Crider's notable coworkers include Michael Ankersen and Carsten Enggaard Stidsen. Their collaborative efforts enhance the research environment and foster innovation within the company.
Conclusion
Albert Michael Crider's contributions to somatostatin research exemplify the vital role of inventors in advancing medical science. His patents and work at Novo Nordisk A/S reflect a commitment to improving healthcare outcomes through innovative solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile